Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated: Examining Key Revenue Metrics

Comparing revenue growth of Takeda and Ligand from 2014-2023.

__timestampLigand Pharmaceuticals IncorporatedTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014645380001777824000000
Thursday, January 1, 2015719140001807378000000
Friday, January 1, 20161089730001732051000000
Sunday, January 1, 20171411020001770531000000
Monday, January 1, 20182514530002097224000000
Tuesday, January 1, 20191202820003291188000000
Wednesday, January 1, 20201864190003197812000000
Friday, January 1, 20212771330003569006000000
Saturday, January 1, 20221962450004027478000000
Sunday, January 1, 20231313140004263762000000
Monday, January 1, 20244263762000000
Loading chart...

Data in motion

A Tale of Two Pharmaceuticals: Revenue Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. This analysis compares the annual revenue trends of Takeda Pharmaceutical Company Limited and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Takeda, a global leader, has consistently outperformed Ligand, with revenues peaking at approximately $4.26 trillion in 2023, marking a 140% increase from 2014. In contrast, Ligand's revenue, while growing, reached a high of $277 million in 2021, a 330% increase from its 2014 figures. This stark contrast highlights Takeda's expansive market reach and strategic acquisitions, while Ligand's growth reflects its niche focus and innovative partnerships. Notably, 2024 data for Ligand is missing, indicating potential reporting delays or strategic shifts. As the pharmaceutical industry evolves, these trends underscore the diverse strategies companies employ to navigate market challenges and opportunities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025